A detailed history of Mather Group, Llc. transactions in Genmab A/S stock. As of the latest transaction made, Mather Group, Llc. holds 80 shares of GMAB stock, worth $1,647. This represents 0.0% of its overall portfolio holdings.

Number of Shares
80
Previous 80 -0.0%
Holding current value
$1,647
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 08, 2024

SELL
$25.13 - $30.27 $728 - $877
-29 Reduced 26.61%
80 $2,000
Q1 2024

Apr 08, 2024

BUY
$26.43 - $32.77 $2,880 - $3,571
109 New
109 $3,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Mather Group, Llc. Portfolio

Follow Mather Group, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mather Group, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Mather Group, Llc. with notifications on news.